{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:08:59Z","timestamp":1791605339162,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00198-022-06642-1","type":"journal-article","created":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T01:02:26Z","timestamp":1672448546000},"page":"563-572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis"],"prefix":"10.1007","volume":"34","author":[{"given":"Masafumi","family":"Kashii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kamatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Nagayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Miyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2426-1024","authenticated-orcid":false,"given":"Kosuke","family":"Ebina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,31]]},"reference":[{"key":"6642_CR1","doi-asserted-by":"crossref","unstructured":"Meier C, Uebelhart B, Aubry-Rozier B, Birkhauser M, Bischoff-Ferrari HA, Frey D, Kressig RW, Lamy O, Lippuner K, Stute P, Suhm N, Ferrari S (2017) Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO\/ASCO. Swiss Med Wkly 147: w14484","DOI":"10.4414\/smw.2017.14484"},{"key":"6642_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/jbmr.3877","volume":"35","author":"RB Conley","year":"2020","unstructured":"Conley RB, Adib G, Adler RA, Akesson KE, Alexander IM, Amenta KC, Blank RD, Brox WT, Carmody EE, Chapman-Novakofski K, Clarke BL, Cody KM, Cooper C, Crandall CJ, Dirschl DR, Eagen TJ, Elderkin AL, Fujita M, Greenspan SL, Halbout P, Hochberg MC, Javaid M, Jeray KJ, Kearns AE, King T, Koinis TF, Koontz JS, Kuzma M, Lindsey C, Lorentzon M, Lyritis GP, Michaud LB, Miciano A, Morin SN, Mujahid N, Napoli N, Olenginski TP, Puzas JE, Rizou S, Rosen CJ, Saag K, Thompson E, Tosi LL, Tracer H, Khosla S, Kiel DP (2020) Secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition. J Bone Miner Res 35:36\u201352","journal-title":"J Bone Miner Res"},{"key":"6642_CR3","doi-asserted-by":"publisher","first-page":"S605","DOI":"10.1007\/s00198-010-1398-8","volume":"21","author":"TP Ip","year":"2010","unstructured":"Ip TP, Leung J, Kung AW (2010) Management of osteoporosis in patients hospitalized for hip fractures. Osteoporos Int 21:S605-614","journal-title":"Osteoporos Int"},{"key":"6642_CR4","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","volume":"8","author":"DM Black","year":"2020","unstructured":"Black DM, Bauer DC, Vittinghoff E, Lui LY, Grauer A, Marin F, Khosla S, de Papp A, Mitlak B, Cauley JA, McCulloch CE, Eastell R, Bouxsein ML (2020) Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. Lancet Diabetes Endocrinol 8:672\u2013682","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6642_CR5","doi-asserted-by":"crossref","unstructured":"Cosman F (2020) Anabolic therapy and optimal treatment sequences for patients with osteoporosis at high risk for fracture. Endocr Pract 26:777\u2013786","DOI":"10.4158\/EP-2019-0596"},{"key":"6642_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","volume":"31","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Harvey NC, McCloskey E, Bruyere O, Veronese N, Lorentzon M, Cooper C, Rizzoli R, Adib G, Al-Daghri N, Campusano C, Chandran M, Dawson-Hughes B, Javaid K, Jiwa F, Johansson H, Lee JK, Liu E, Messina D, Mkinsi O, Pinto D, Prieto-Alhambra D, Saag K, Xia W, Zakraoui L, Reginster J (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31:1\u201312","journal-title":"Osteoporos Int"},{"key":"6642_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420","journal-title":"N Engl J Med"},{"key":"6642_CR8","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","volume":"399","author":"IR Reid","year":"2022","unstructured":"Reid IR, Billington EO (2022) Drug therapy for osteoporosis in older adults. Lancet 399:1080\u20131092","journal-title":"Lancet"},{"key":"6642_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11914-021-00663-1","volume":"19","author":"F Cosman","year":"2021","unstructured":"Cosman F, Dempster DW (2021) Anabolic agents for postmenopausal osteoporosis: how do you choose? Curr Osteoporos Rep 19:189\u2013205","journal-title":"Curr Osteoporos Rep"},{"key":"6642_CR10","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"6642_CR11","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jbmr.3427","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman F, Crittenden DB, Ferrari S, Khan A, Lane NE, Lippuner K, Matsumoto T, Milmont CE, Libanati C, Grauer A (2018) FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Miner Res 33:1219\u20131226","journal-title":"J Bone Miner Res"},{"key":"6642_CR12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00774-020-01147-5","volume":"39","author":"A Miyauchi","year":"2021","unstructured":"Miyauchi A, Hamaya E, Yang W, Nishi K, Libanati C, Tolman C, Shimauchi J (2021) Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial. J Bone Miner Metab 39:278\u2013288","journal-title":"J Bone Miner Metab"},{"key":"6642_CR13","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1002\/jbmr.3176","volume":"32","author":"TM Keaveny","year":"2017","unstructured":"Keaveny TM, Crittenden DB, Bolognese MA, Genant HK, Engelke K, Oliveri B, Brown JP, Langdahl BL, Yan C, Grauer A, Libanati C (2017) Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass. J Bone Miner Res 32:1956\u20131962","journal-title":"J Bone Miner Res"},{"key":"6642_CR14","doi-asserted-by":"publisher","first-page":"115574","DOI":"10.1016\/j.bone.2020.115574","volume":"140","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hirao M, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S, Miyama A, Nakaya H, Kunugiza Y, Okamura G, Etani Y, Takami K, Goshima A, Nakata K (2020) Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone 140:115574","journal-title":"Bone"},{"key":"6642_CR15","doi-asserted-by":"publisher","first-page":"105219","DOI":"10.1016\/j.jbspin.2021.105219","volume":"88","author":"K Ebina","year":"2021","unstructured":"Ebina K, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S, Miyama A, Nakaya H, Kunugiza Y, Hirao M, Okamura G, Etani Y, Takami K, Goshima A, Miura T, Nakata K, Okada S (2021) Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis. Joint Bone Spine 88:105219","journal-title":"Joint Bone Spine"},{"key":"6642_CR16","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s00198-021-05925-3","volume":"32","author":"A Tominaga","year":"2021","unstructured":"Tominaga A, Wada K, Okazaki K, Nishi H, Terayama Y, Kato Y (2021) Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study. Osteoporos Int 32:1999\u20132009","journal-title":"Osteoporos Int"},{"key":"6642_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","volume":"31","author":"S Soen","year":"2013","unstructured":"Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, Endo N, Gorai I, Shiraki M, Hagino H, Hosoi T, Ohta H, Yoneda T, Tomomitsu T (2013) Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab 31:247\u2013257","journal-title":"J Bone Miner Metab"},{"key":"6642_CR18","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137\u20131148","journal-title":"J Bone Miner Res"},{"key":"6642_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jocd.2016.03.003","volume":"19","author":"EM Lewiecki","year":"2016","unstructured":"Lewiecki EM, Binkley N, Morgan SL, Shuhart CR, Camargos BM, Carey JJ, Gordon CM, Jankowski LG, Lee JK, Leslie WD (2016) Best practices for dual-energy X-ray absorptiometry measurement and reporting: International Society for Clinical Densitometry Guidance. J Clin Densitom 19:127\u2013140","journal-title":"J Clin Densitom"},{"key":"6642_CR20","first-page":"11","volume":"33","author":"K Ebina","year":"2022","unstructured":"Ebina K, Etani Y, Tsuboi H, Nagayama Y, Kashii M, Miyama A, Kunugiza Y, Hirao M, Okamura G, Noguchi T, Takami K, Goshima A, Miura T, Fukuda Y, Kurihara T, Okada S, Nakata K (2022) Impact of the duration of previous osteoporosis treatment on the effect of romosozumab in patients with postmenopausal osteoporosis. Osteoporos Int 33:11\u20132441","journal-title":"Osteoporos Int"},{"key":"6642_CR21","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1007\/s00198-022-06386-y","volume":"33","author":"K Ebina","year":"2022","unstructured":"Ebina K, Etani Y, Tsuboi H, Nagayama Y, Kashii M, Miyama A, Kunugiza Y, Hirao M, Okamura G, Noguchi T, Takami K, Goshima A, Miura T, Fukuda Y, Kurihara T, Okada S, Nakata K (2022) Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis. Osteoporos Int 33:1807\u20131813","journal-title":"Osteoporos Int"},{"key":"6642_CR22","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1080\/14397595.2019.1657653","volume":"30","author":"C Yukioka","year":"2020","unstructured":"Yukioka C, Ebina K, Shimaoka Y, Yukioka M, Yoshikawa H, Nakata K, Ochi T (2020) Establishment of anti-C1q monoclonal antibodies to measure serum C1q levels discriminating disease severity subsets of rheumatoid arthritis within 5 years of onset. Mod Rheumatol 30:816\u2013820","journal-title":"Mod Rheumatol"},{"key":"6642_CR23","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/jbmr.2480","volume":"30","author":"MS Ominsky","year":"2015","unstructured":"Ominsky MS, Libanati C, Niu QT, Boyce RW, Kostenuik PJ, Wagman RB, Baron R, Dempster DW (2015) Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab. J Bone Miner Res 30:1280\u20131289","journal-title":"J Bone Miner Res"},{"key":"6642_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","volume":"96","author":"J Delgado-Calle","year":"2017","unstructured":"Delgado-Calle J, Sato AY, Bellido T (2017) Role and mechanism of action of sclerostin in bone. Bone 96:29\u201337","journal-title":"Bone"},{"key":"6642_CR25","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s001980070026","volume":"11","author":"A Coin","year":"2000","unstructured":"Coin A, Sergi G, Beninca P, Lupoli L, Cinti G, Ferrara L, Benedetti G, Tomasi G, Pisent C, Enzi G (2000) Bone mineral density and body composition in underweight and normal elderly subjects. Osteoporos Int 11:1043\u20131050","journal-title":"Osteoporos Int"},{"key":"6642_CR26","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00198-017-4351-2","volume":"29","author":"K Uenishi","year":"2018","unstructured":"Uenishi K, Tokiwa M, Kato S, Shiraki M (2018) Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis. Osteoporos Int 29:723\u2013732","journal-title":"Osteoporos Int"},{"key":"6642_CR27","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00296-006-0288-z","volume":"27","author":"JD Ringe","year":"2007","unstructured":"Ringe JD, Farahmand P, Schacht E, Rozehnal A (2007) Superiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin D or alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int 27:425\u2013434","journal-title":"Rheumatol Int"},{"key":"6642_CR28","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00774-016-0792-5","volume":"35","author":"K Ebina","year":"2017","unstructured":"Ebina K, Kashii M, Hirao M, Hashimoto J, Noguchi T, Koizumi K, Kitaguchi K, Matsuoka H, Iwahashi T, Tsukamoto Y, Yoshikawa H (2017) Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis. J Bone Miner Metab 35:571\u2013580","journal-title":"J Bone Miner Metab"},{"key":"6642_CR29","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1080\/14397595.2017.1308454","volume":"28","author":"T Suzuki","year":"2018","unstructured":"Suzuki T, Nakamura Y, Tanaka M, Kamimura M, Ikegami S, Uchiyama S, Kato H (2018) Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis. Mod Rheumatol 28:376\u2013379","journal-title":"Mod Rheumatol"},{"key":"6642_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00198-016-3692-6","volume":"28","author":"C Gao","year":"2017","unstructured":"Gao C, Qiao J, Li SS, Yu WJ, He JW, Fu WZ, Zhang ZL (2017) The levels of bone turnover markers 25(OH)D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China. Osteoporos Int 28:211\u2013218","journal-title":"Osteoporos Int"},{"key":"6642_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.bone.2017.04.005","volume":"101","author":"RW Boyce","year":"2017","unstructured":"Boyce RW, Niu QT, Ominsky MS (2017) Kinetic reconstruction reveals time-dependent effects of romosozumab on bone formation and osteoblast function in vertebral cancellous and cortical bone in cynomolgus monkeys. Bone 101:77\u201387","journal-title":"Bone"},{"key":"6642_CR32","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1007\/s00198-014-2819-x","volume":"25","author":"K Ebina","year":"2014","unstructured":"Ebina K, Hashimoto J, Shi K, Kashii M, Hirao M, Yoshikawa H (2014) Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients. Osteoporos Int 25:2755\u20132765","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06642-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-022-06642-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06642-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T17:10:54Z","timestamp":1675876254000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-022-06642-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,31]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["6642"],"URL":"https:\/\/doi.org\/10.1007\/s00198-022-06642-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,31]]},"assertion":[{"value":"14 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"MK has received payments for lectures from Amgen, Asahi-Kasei, Astellas, Mochida, and Teijin Pharma. KE is affiliated with the Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, which is supported by Taisho. KE has received research grants from Amgen, Asahi-Kasei, Astellas, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, and Ono. KE has received payments for lectures from Amgen, Asahi-Kasei, Astellas, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Ono, and Pfizer. HT has received a research grant from Chugai and has received payments for lectures from Asahi-Kasei, Astellas, Chugai, Eisai, Eli Lilly, and Pfizer. YN has received payments for lectures from Asahi-Kasei, Astellas, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, and Ono. TK and AM declare that they have no conflicts of interest. The funders had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}